Intragastric Balloon therapy for treatment of Obesity

1. Intragastric balloon therapy for treatment
of obesity
Presented by
Dhanashree R. Kavhale
M. Pharm. (Pharmaceutical Chemistry) II yr
Department of Pharmaceutical Sciences
Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur – 440 033

2. 2

3. Content
 Introduction
 Intragastric Ballon
 Types of IGB’s
 Mechanism
 Balloon Insertion And Removal
 Impact on weight reduction
 Conclusion
 References
3

4. Introduction
 Obesity is a medical condition in which
excess body fat has accumulated to an
extent that it may have a more side effects
on health.
 Body mass index (BMI) calculated as
weight in kilograms divided by the square
of height in meters of 30 kg/𝑚2 or greater.
 Increasing rates in adults and children.
4
Fig 1: Body mass index

5.  Patients with bezoars often complained of post prandial fullness, nausea and
vomiting.
 Garren-Edwards Gastric Bubble, a cylindrical, polyurethane contrivance,
inflated with air.
 The first swallowable intragastric balloon is Obalon.
 Devices have strong safety profile and low rate of post-placement
symptoms.
 IGBs are approved for (BMI) of 30 to 40 kg/m2.
5

6. Intragastric balloon
 First generation IBG’s shows adverse effects including
gastric perforations and intestinal obstructions.
 Second Generation IBG’s are safer and more effective
IGBs.
 These balloons are made of more durable silicone-based
material and filled with saline or air.
 The Bioenterics Intragastric Balloon, a fluid-filled
single balloon, marketed in the United States as the
Orbera Intragastric Balloon System.
6
Fig 2: placement of IGB

7. Types of IGB’s with specifications 7
Fig 3: Different types of 2nd generation IGB’s

8. Features of Obalon balloon 8

9. 9
Fig 4 : Obalon Balloon Capsule view Fig 5 : Comparison of size with vitamin E Gel capsule

10. Balloon Insertion 10

11. 11
Fig 6 (a) : Insertion of Obalon capsule Fig 6 (b) : IGB with catheter

12. Mechanism 12
Promote weight
loss by
Decreasing stomach
potential volume
Change in other
hormones
Gastric emptying
Change in appetite
regulating hormones

13. Balloon Removal
 These balloons will take up more space in stomach
to help lose weight.
 All balloons are taken out 6 months after the
first balloon capsule is swallowed.
 By using light anesthesia, by puncture all the
balloons get deflated one by one.
 Taking all three balloons out of stomach typically
takes less than 20 minutes.
13
Fig 7: Deflated Obalon Balloon
removal

14. Impact on weight reduction
 The Obalon showed median weight losses after 4 weeks, 8 weeks, and 12 weeks
as 2.2 kg, 4.0 kg, and 5 kg, respectively.
 significant improvement in fasting glucose, low-density lipoprotein cholesterol,
systolic blood pressure and triglycerides at the 24-week mark.
 Obalon device can be used starting at a lower threshold BMI (>30) respect to
BIB or other intragastric balloons.
 It has lower side effect and complication rates.
14

15. Conclusion
 Obalon It offers a minimally invasive and effective method for managing
obesity and associated conditions with moderate weight loss and minimum side
effects.
 Obalon can be administered easily without complications, inducing an
appreciable weight loss with a statistically significant reduction in BMI and an
improvement in associated comorbidities.
15

16. References 16
 D. Kavhale, D. Lahoti, J. Ambhore, and S. Gandhi, “A critical review on the intragastric
balloon therapy for treatment of obesity,” International Journal of Advances in
Engineering and Management (IJAEM), vol. 2, no. 5, pp. 721–727, Oct. 2020, doi:
10.35629/5252-0205721727.
 F. S. Luppino et al., “Overweight, Obesity, and Depression,” Arch Gen Psychiatry, vol.
67, no. 3, pp. 220–222, Mar. 2010, doi: 10.1001/archgenpsychiatry.2010.2.
 S. Z. Yanovski and J. A. Yanovski, “Long-term Drug Treatment for Obesity,” JAMA, vol.
311, no. 1, pp. 71–74, Jan. 2014, doi: 10.1001/jama.2013.281361.
 D. Vyas, K. Deshpande, and Y. Pandya, “Advances in endoscopic balloon therapy for
weight loss and its limitations,” World J Gastroenterol, vol. 23, no. 44, pp. 7813–7817,
Nov. 2017, doi: 10.3748/wjg.v23.i44.7813.
 M. G. Farina et al., “Intragastric Balloon in Association with Lifestyle and/or
Pharmacotherapy in the Long-Term Management of Obesity,” Obes Surg, vol. 22, no. 4,
pp. 565–571, Apr. 2012, doi: 10.1007/s11695-011-0514-y.

17. Thank You
17